Avalo Therapeutics Files 8-K
Ticker: AVTX · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: AVLO
TL;DR
AVLO filed an 8-K, standard procedure, no major news yet.
AI Summary
Avalo Therapeutics, Inc. filed an 8-K on December 5, 2024, reporting other events and financial statements. The company, formerly known as Cerecor Inc., is incorporated in Delaware and headquartered in Rockville, Maryland. This filing does not appear to contain specific transactional or financial details beyond the reporting of these items.
Why It Matters
This filing indicates Avalo Therapeutics is fulfilling its reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for reporting events and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Rockville, Maryland (location) — Principal executive offices
- December 5, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Avalo Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 5, 2024.
When was Avalo Therapeutics, Inc. incorporated?
Avalo Therapeutics, Inc. is incorporated in Delaware.
What was Avalo Therapeutics, Inc.'s former company name?
Avalo Therapeutics, Inc.'s former company name was Cerecor Inc.
Where are Avalo Therapeutics, Inc.'s principal executive offices located?
Avalo Therapeutics, Inc.'s principal executive offices are located at 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
What is the SEC file number for Avalo Therapeutics, Inc.?
The SEC file number for Avalo Therapeutics, Inc. is 001-37590.
Filing Stats: 421 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-12-05 07:03:53
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20241205.htm (8-K) — 25KB
- ex-991_avtxcorporatepres.htm (EX-99.1) — 30KB
- ex-991_avtxcorporatepres001.jpg (GRAPHIC) — 93KB
- ex-991_avtxcorporatepres002.jpg (GRAPHIC) — 152KB
- ex-991_avtxcorporatepres003.jpg (GRAPHIC) — 138KB
- ex-991_avtxcorporatepres004.jpg (GRAPHIC) — 124KB
- ex-991_avtxcorporatepres005.jpg (GRAPHIC) — 114KB
- ex-991_avtxcorporatepres006.jpg (GRAPHIC) — 152KB
- ex-991_avtxcorporatepres007.jpg (GRAPHIC) — 49KB
- ex-991_avtxcorporatepres008.jpg (GRAPHIC) — 146KB
- ex-991_avtxcorporatepres009.jpg (GRAPHIC) — 122KB
- ex-991_avtxcorporatepres010.jpg (GRAPHIC) — 135KB
- ex-991_avtxcorporatepres011.jpg (GRAPHIC) — 138KB
- ex-991_avtxcorporatepres012.jpg (GRAPHIC) — 118KB
- ex-991_avtxcorporatepres013.jpg (GRAPHIC) — 175KB
- ex-991_avtxcorporatepres014.jpg (GRAPHIC) — 137KB
- ex-991_avtxcorporatepres015.jpg (GRAPHIC) — 175KB
- ex-991_avtxcorporatepres016.jpg (GRAPHIC) — 175KB
- ex-991_avtxcorporatepres017.jpg (GRAPHIC) — 68KB
- ex-991_avtxcorporatepres018.jpg (GRAPHIC) — 43KB
- ex-991_avtxcorporatepres019.jpg (GRAPHIC) — 192KB
- ex-991_avtxcorporatepres020.jpg (GRAPHIC) — 35KB
- ex-991_avtxcorporatepres021.jpg (GRAPHIC) — 138KB
- ex-991_avtxcorporatepres022.jpg (GRAPHIC) — 37KB
- ex-991_avtxcorporatepres023.jpg (GRAPHIC) — 30KB
- ex-991_avtxcorporatepres024.jpg (GRAPHIC) — 116KB
- 0001628280-24-049979.txt ( ) — 4048KB
- avtx-20241205.xsd (EX-101.SCH) — 2KB
- avtx-20241205_lab.xml (EX-101.LAB) — 21KB
- avtx-20241205_pre.xml (EX-101.PRE) — 12KB
- avtx-20241205_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 5, 2024, Avalo Therapeutics, Inc. (the "Company") posted on its website an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Investor Presentation. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: December 5, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2